IRIS
RUGGIERO, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.362
EU - Europa 2.967
NA - Nord America 2.473
SA - Sud America 568
AF - Africa 114
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.489
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.427
US - Stati Uniti d'America 2.385
RU - Federazione Russa 1.658
CN - Cina 988
BR - Brasile 473
IT - Italia 422
DE - Germania 354
HK - Hong Kong 344
VN - Vietnam 193
IN - India 153
FI - Finlandia 109
NL - Olanda 106
KR - Corea 99
GB - Regno Unito 87
FR - Francia 49
MX - Messico 39
AR - Argentina 38
CI - Costa d'Avorio 36
CA - Canada 35
UA - Ucraina 34
ZA - Sudafrica 33
BD - Bangladesh 30
PL - Polonia 28
JP - Giappone 27
SE - Svezia 27
IE - Irlanda 22
TR - Turchia 15
BG - Bulgaria 14
EC - Ecuador 13
ID - Indonesia 12
PK - Pakistan 11
KE - Kenya 10
AT - Austria 9
ES - Italia 9
IQ - Iraq 9
CL - Cile 8
JO - Giordania 8
MA - Marocco 8
PY - Paraguay 8
VE - Venezuela 8
CO - Colombia 7
PE - Perù 7
EG - Egitto 6
RS - Serbia 6
LT - Lituania 5
IL - Israele 4
PT - Portogallo 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BE - Belgio 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EE - Estonia 3
MK - Macedonia 3
MY - Malesia 3
OM - Oman 3
PA - Panama 3
TN - Tunisia 3
UY - Uruguay 3
UZ - Uzbekistan 3
AF - Afghanistan, Repubblica islamica di 2
AU - Australia 2
BB - Barbados 2
BY - Bielorussia 2
CG - Congo 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NP - Nepal 2
SN - Senegal 2
TJ - Tagikistan 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CH - Svizzera 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EU - Europa 1
GL - Groenlandia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MQ - Martinica 1
MR - Mauritania 1
MZ - Mozambico 1
NC - Nuova Caledonia 1
Totale 10.475
Salva come PNG Salva come JPEG
Città #
Singapore 1.216
Hefei 479
Moscow 445
Hong Kong 341
Santa Clara 288
Ashburn 274
Beijing 240
Chandler 191
Munich 131
Seoul 95
Kochi 85
Amsterdam 78
Helsinki 71
Los Angeles 71
Ho Chi Minh City 69
Boston 62
Naples 59
Redondo Beach 58
Lawrence 55
San Jose 53
Buffalo 52
Millbury 43
São Paulo 41
Napoli 40
Hanoi 39
Milan 39
Rome 39
Seattle 36
Dallas 35
Des Moines 34
The Dalles 28
Düsseldorf 26
Houston 24
Krefeld 23
New York 23
Chicago 22
Rio de Janeiro 21
Falkenstein 19
Lappeenranta 19
Mexico City 18
Montreal 18
Tokyo 17
Warsaw 17
Chennai 16
Council Bluffs 16
Wilmington 16
Atlanta 15
Dublin 15
Orem 15
Johannesburg 14
Turin 14
Woodbridge 14
Brooklyn 13
Fairfield 13
Phoenix 13
Washington 13
Haiphong 12
Sofia 12
Stockholm 12
Turku 12
Brasília 11
Lauterbourg 11
London 11
Poplar 11
Denver 10
Frankfurt am Main 10
Guangzhou 10
Nairobi 10
Nuremberg 10
Pune 10
San Francisco 10
Arezzo 9
Biên Hòa 9
Kronberg 9
Menlo Park 9
Mumbai 9
Amman 8
Belo Horizonte 8
Boardman 8
Cagliari 8
Campinas 8
Florence 8
Portsmouth 8
Xi'an 8
Ankara 7
Karlsruhe 7
Magenta 7
Rochdale 7
Salvador 7
Santo André 7
Toronto 7
Bengaluru 6
Da Nang 6
Freiburg im Breisgau 6
Fremont 6
Guayaquil 6
Manchester 6
Mauá 6
Porto Alegre 6
Querétaro 6
Totale 5.595
Salva come PNG Salva come JPEG
Nome #
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose 256
Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection 227
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence 144
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study 127
Persistent candidiasis infection during anti‐ IL ‐17 treatment for plaque psoriasis requiring biologic discontinuation: a case series and literature review 115
QuantiFERON TB‐gold conversion rate among psoriasis patients under biologics: a 9‐year retrospective study 114
The efficacy and safety of abrocitinib as a treatment option for atopic dermatitis: A short report of the clinical data 110
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears 108
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 107
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 106
A case of linear psoriasis in a young patient with Down syndrome and review of the literature 106
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 106
Corrigendum: A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab (Clin Cosmet Investig Dermatol. (2023), 16, (3503–3507), 10.2147/CCID.S447123) 105
Teledermatology for acne during COVID-19: high patients' satisfaction in spite of the emergency 104
Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role? 104
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 103
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 103
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 103
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation 102
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas 101
Low dose oral corticosteroids, microneedling, and topical 5-fluorouracil: A novel treatment for recalcitrant pediatric vitiligo 101
Giant nodular melanoma of the nose in a 78‐year old female refusing complete excision 99
Management of Psoriasis Patients with Serious Infectious Diseases 98
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 98
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 98
Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa 98
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 97
QuantiFERON TB-gold conversion is not uncommon in psoriasis patients under anti-TNF-α 96
Anti‐interleukin‐23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice 96
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 96
Impact of current anti-psoriatic systemic treatments on male and female fertility: what the endocrinologist needs to know 95
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 95
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 93
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 92
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review 92
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge 91
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al 91
Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report 90
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period 90
A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: should treatment be discontinued? 90
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study 89
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 89
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 88
A case of severe psoriasis in a 84-year old women successfully treated with ixekizumab 87
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders 87
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 86
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis 86
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? 86
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 85
The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre 85
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 85
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? 85
Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome 85
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 84
Teledermatology and chronic skin diseases: real life experience in a Southern Italian Dermatologic Centre 84
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 83
Etanercept for pediatric acrodermatitis continua of Hallopeau: a case report and literature review 83
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 81
A case of erythrodermic psoriasis successfully treated with guselkumab 81
JAK Inhibitors in Psoriatic Disease 80
Reply to ‘Impact of the French COVID ‐19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier et al 80
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation 80
Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Küster-Hauser Syndrome: Insight into the Role of Hormones in HS 80
A case of erythrodermic psoriasis successfully treated with apremilast 80
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study 79
A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus 78
New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding 78
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? 78
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study 77
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 77
Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic 77
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire 75
Comment on 'Morphoea following COVID-19 vaccination' 75
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 75
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis 75
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 75
The Past, the Present and the Future of Teledermatology: A Narrative Review 74
Telemedicine and support groups could be used to improve adherence to treatment and health-related quality of life in patients affected by inflammatory skin conditions during the COVID-19 pandemic 74
An atypical ear nodule 74
Author reply to: Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?' 73
Dupilumab associated inflammatory arthritis: a literature review 73
Reply to "Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center" by Sotiriou E et al 73
Cutaneous Squamous Cell Carcinoma: From Diagnosis to Follow-Up 72
Safety of dupilumab in atopic patients during COVID-19 outbreak 72
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 71
A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab 71
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin Scars 71
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa' 71
New frontiers in personalized medicine in psoriasis 69
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 69
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study 69
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al 68
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 68
Patient satisfaction with remote dermatology consultations during the COVID-19 pandemic. Comment on 'A qualitative assessment of patient satisfaction with remote dermatology consultations used during the UK's first wave of the COVID-19 pandemic in a single, secondary-care dermatology department' 67
Chronic cutaneous ulcers management in dermatologic department during COVID-19 era 67
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 66
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 64
ChatGPT and Dermatology: friends or foes? 63
Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series 63
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data 63
Totale 8.950
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021120 0 0 0 0 0 0 5 54 9 35 17 0
2021/2022322 2 2 3 13 22 23 2 20 4 44 45 142
2022/2023684 59 43 35 24 68 70 57 80 91 81 56 20
2023/2024755 32 97 83 67 42 70 21 74 23 27 133 86
2024/20254.215 211 226 30 34 123 301 419 321 340 468 1.419 323
2025/20264.454 842 769 738 679 1.062 286 78 0 0 0 0 0
Totale 10.654